Navigation Links
Ortho-McNeil initiates first-of-its-kind skin infection registry
Date:8/6/2008

Raritan, NJ, August 6, 2008 The nation's first, prospective registry of complicated skin and soft tissue infections (cSSTIs), known as SSTIR (the Skin and Soft Tissue Infection Hospital Registry), has begun enrolling patients. The SSTIR, plans to enroll more than 1,200 hospitalized patients by the end of this year, and is designed to better understand treatment patterns and provide data to help improve patient outcomes. The registry is sponsored by Ortho-McNeil, division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

More than 50 hospitals nationwide will participate in this prospective, multi-center registry, which will comprehensively characterize the four major types of cSSTIs: diabetic foot infections, surgical site infections, deep soft tissue abscesses and cellulitis (an infection of tissue under the skin). In addition, the study will observe patient management in the hospital setting, including selection and timing of antibiotic treatment, changes in treatment regimen, outcomes, and economic impact.

"Physicians are treating more and more patients with complicated skin infections in hospitals across the U.S., and the emergence of resistant pathogens has made the situation even more complex," said Susan Nicholson, M.D., Therapeutic Area Leader, Internal Medicine, Ortho-McNeil, division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. "This data will give physicians insight into how to manage these difficult-to-treat infections and understand current treatment patterns in order to provide consensus on how best to care for patients."

Complicated skin and soft tissue infections account for almost 10 percent of all hospital admissions in the U.S. The most common types of cSSTIs are post-operative surgical site infections, which represent up to 25 percent of all hospital infections. Cellulitis and soft tissue abscesses are among the most common reasons for emergency department visits.

According to the National Institutes of Health, 111,000 people with diabetes are hospitalized with foot infections each year, and as many as 3.09 million adults will develop a diabetic foot infection in their lifetime.

The increased incidence of one of the most common resistant bacteria that are causing cSSTI, methicillin-resistant Staphylococcus aureus (MRSA), poses a significant challenge and burden to the U.S. health care system. Despite the high incidence of cSSTIs, a limited understanding remains and a wide variety of treatment options are used which often affect patient outcomes.

The emergence of resistant bacteria has created a need for new antibiotics and treatment strategies. As such, treatment choices made by physicians can significantly impact how patients with cSSTI respond to care.


'/>"/>

Contact: Amy Firsching
908-218-7583
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Source:Eurekalert

Related medicine news :

1. Isis Announces HSR Approval and Closure of Its Collaboration With Ortho-McNeil, Inc.
2. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
3. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
4. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
5. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
6. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
7. Harbinger Research Initiates Coverage on HearAtLast
8. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
9. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
10. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
11. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... , ... July 24, 2017 , ... ... office at 2307 Bellmore Avenue, Bellmore, New York, (516) 784-5858. The office opened ... M.D. and physician assistants Lori Friedman and Fruma Leah Wiederman. , Advanced ...
(Date:7/24/2017)... ... ... “Nana Nana Boo Boo”: a delightful tale of a young girl who ... Boo” is the creation of published author Michael Rush, a Deputy Sheriff, former world ... Rush’s new book presents the importance of manners in a way easily understood by ...
(Date:7/24/2017)... , ... July 24, 2017 , ... “Journey to the ... odyssean novel that details a young woman’s path to finding herself. “Journey to ... creation of published author, Jamie Grayson, an experienced writer of newsletters, manuals, and articles, ...
(Date:7/23/2017)... ... July 24, 2017 , ... ... Physicists in Medicine (AAPM) 59th Annual Meeting & Exhibition, to be held in ... physics profession, hospital administrators and journalists can visit the AAPM Facebook page to ...
(Date:7/23/2017)... ... July 23, 2017 , ... A 20-year-long study ... Louis, and led by the Minneapolis Veterans Administration Health Care System overwhelmingly supports growing ... disease offers very few benefits. , In the cases involved with this study, ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade cell and tissue hypothermic ... today announced that it has reached an agreement with ... shareholder, to modify its existing credit facility effective June ... WAVI agreed to exchange its existing $4.25 million credit ...
(Date:6/30/2017)... , June 30, 2017 In vitro ... the start of May, at least ten diagnostic companies ... private investments, public offerings and a loan facility.  The ... to almost $80 million.  Kalorama Information provides a monthly ... its Diagnostics Knowledge Center. ...
(Date:6/30/2017)... 29, 2017  Axium Pharmaceuticals Inc. is a pharmaceutical company aimed ... and alternative dosage forms of existing biologically active molecule. ... ... waterless self-nano emulsifying formula, which is designed to prevent precipitation ... the spray will provide fast onset of action and is ...
Breaking Medicine Technology: